Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

202 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Introduction. Trabectedin treatment in GYN cancers.
Poveda A. Poveda A. Int J Gynecol Cancer. 2011 May;21 Suppl 1:S1-2. doi: 10.1097/IGC.0b013e318217b337. Int J Gynecol Cancer. 2011. PMID: 21540665 Review.
Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial.
Poveda AM, Selle F, Hilpert F, Reuss A, Savarese A, Vergote I, Witteveen P, Bamias A, Scotto N, Mitchell L, Pujade-Lauraine E. Poveda AM, et al. J Clin Oncol. 2015 Nov 10;33(32):3836-8. doi: 10.1200/JCO.2015.63.1408. Epub 2015 Aug 17. J Clin Oncol. 2015. PMID: 26282651 Clinical Trial. No abstract available.
Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.
Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Lisyanskaya AS, Makhson AN, Rolski J, Gorbounova VA, Ghatage P, Bidzinski M, Shen K, Ngan HY, Vergote IB, Nam JH, Park YC, Lebedinsky CA, Poveda AM. Monk BJ, et al. J Clin Oncol. 2010 Jul 1;28(19):3107-14. doi: 10.1200/JCO.2009.25.4037. Epub 2010 Jun 1. J Clin Oncol. 2010. PMID: 20516432 Clinical Trial.
PATIENTS AND METHODS: Women > or = 18 years, stratified by performance status (0 to 1 v 2) and platinum sensitivity, were randomly assigned to receive an intravenous infusion of PLD 30 mg/m(2) followed by a 3-hour infusion of trabectedin 1.1 mg/m(2) every 3 weeks or PLD …
PATIENTS AND METHODS: Women > or = 18 years, stratified by performance status (0 to 1 v 2) and platinum sensitivity, were randomly assign …
Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis.
Monk BJ, Herzog TJ, Kaye SB, Krasner CN, Vermorken JB, Muggia FM, Pujade-Lauraine E, Park YC, Parekh TV, Poveda AM. Monk BJ, et al. Eur J Cancer. 2012 Oct;48(15):2361-8. doi: 10.1016/j.ejca.2012.04.001. Epub 2012 Apr 26. Eur J Cancer. 2012. PMID: 22541893 Clinical Trial.
The study was powered to show a 33% increase in overall survival (OS) after 520 deaths had occurred. RESULTS: After a median follow-up of 47.4 months, there were 522 deaths among 672 subjects. ...In another unplanned exploratory analysis, the subset of patients with …
The study was powered to show a 33% increase in overall survival (OS) after 520 deaths had occurred. RESULTS: After a median f …
A retrospective analysis of antitumour activity with trabectedin in translocation-related sarcomas.
Le Cesne A, Cresta S, Maki RG, Blay JY, Verweij J, Poveda A, Casali PG, Balaña C, Schöffski P, Grosso F, Lardelli P, Nieto A, Alfaro V, Demetri GD. Le Cesne A, et al. Eur J Cancer. 2012 Nov;48(16):3036-44. doi: 10.1016/j.ejca.2012.05.012. Epub 2012 Jun 29. Eur J Cancer. 2012. PMID: 22749255
Patients received a median of 4 trabectedin cycles (range, 1-48; median dose intensity=0.40 mg/m(2)/week). Partial responses according to Response Evaluation Criteria in Solid Tumours (RECIST) occurred in 8 patients (ORR=10%; 95% CI, 4-19%): four in MRC-L-sarcoma; three in …
Patients received a median of 4 trabectedin cycles (range, 1-48; median dose intensity=0.40 mg/m(2)/week). Partial responses accordin …
Reply to F. Tomao et al.
Pujade-Lauraine E, Hilpert F, Poveda A. Pujade-Lauraine E, et al. J Clin Oncol. 2014 Nov 1;32(31):3580. doi: 10.1200/JCO.2014.57.7379. Epub 2014 Sep 2. J Clin Oncol. 2014. PMID: 25185088 No abstract available.
Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma.
Berton-Rigaud D, Devouassoux-Shisheboran M, Ledermann JA, Leitao MM, Powell MA, Poveda A, Beale P, Glasspool RM, Creutzberg CL, Harter P, Kim JW, Reed NS, Ray-Coquard I. Berton-Rigaud D, et al. Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S55-60. doi: 10.1097/IGC.0000000000000228. Int J Gynecol Cancer. 2014. PMID: 25341582 Review.
Prognosis for localized stage disease is poor with a high risk of recurrences, both local and distant, occurring within 1 year. ...For UCs, a comprehensive approach to management is recommended with complete surgical staging followed by systemic chemotherapy in pati …
Prognosis for localized stage disease is poor with a high risk of recurrences, both local and distant, occurring within 1 year. ...Fo …
Platinum or nonplatinum in recurrent ovarian cancer: that is the question.
Poveda A, Marth C. Poveda A, et al. Future Oncol. 2017 Oct;13(23s):11-16. doi: 10.2217/fon-2017-0317. Epub 2017 Oct 11. Future Oncol. 2017. PMID: 29020823 Review.
., a platinum treatment-free interval [TFIp] of 6-12 months). Results of the MITO-8 study called into question the role of single-agent nonplatinum-based regimens in this specific subset of ovarian cancer patients. ...
., a platinum treatment-free interval [TFIp] of 6-12 months). Results of the MITO-8 study called into question the role of single-age …
Treatment of Inoperable Vulvar Cancer: Where We Come From and Where Are We Going.
Martinez-Castro P, Poveda A, Guinot JL, Minig L. Martinez-Castro P, et al. Int J Gynecol Cancer. 2016 Nov;26(9):1694-1698. doi: 10.1097/IGC.0000000000000815. Int J Gynecol Cancer. 2016. PMID: 27575631 Review.
The radical surgeries usually need a long recovery term both in the region of the vulva and in the area of the groin lymph nodes. ...On the other hand, the use of radiotherapy and chemotherapy as a first step treatment can result in a complete elimination of …
The radical surgeries usually need a long recovery term both in the region of the vulva and in the area of the groin lymph nodes. ... …
A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas.
Garcia del Muro X, Lopez-Pousa A, Martin J, Buesa JM, Martinez-Trufero J, Casado A, Poveda A, Cruz J, Bover I, Maurel J; Spanish Group for Research on Sarcomas. Garcia del Muro X, et al. Cancer. 2005 Oct 15;104(8):1706-12. doi: 10.1002/cncr.21384. Cancer. 2005. PMID: 16134177 Clinical Trial.
METHODS: Forty-nine patients with pretreated soft tissue sarcoma (the STS arm) and 18 patients with previously untreated gastrointestinal stromal tumor (the GIST arm) were enrolled onto a 2-arm, multicenter, Phase II study between November 1999 and July 2001. Temozolomide …
METHODS: Forty-nine patients with pretreated soft tissue sarcoma (the STS arm) and 18 patients with previously untreated gastrointestinal st …
202 results
Jump to page
Feedback